05:36 AM EDT, 05/22/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) participated in immuno-oncology company NeoPhore's oversubscribed series B financing extension round, the latter said Wednesday.

NeoPhore did not disclose the financial value of Bristol-Myers Squibb's ( BMY ) investment but said the funding will allow it to explore novel biology associated with the DNA mismatch repair pathway in cancer and advance its pre-clinical studies to deliver a drug candidate in 2025.

Price: 42.33, Change: +0.06, Percent Change: +0.14